Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY: BDX )

224.00 -1.45 (-0.64%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. 
Via Benzinga
Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike
The U.S. 
Via Benzinga
Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth
BD's Q4 sales rose 6.9% to $5.44 billion, beating estimates. EPS of $3.81 also topped forecasts. FY25 guidance includes $21.9 billion-$22.1 billion sales and EPS of $14.25-$14.60. 
Via Benzinga
Price Over Earnings Overview: Becton Dickinson
Via Benzinga
A Glimpse Into The Expert Outlook On Becton Dickinson Through 4 Analysts
Via Benzinga
(BDX) - Analyzing Becton Dickinson's Short Interest
Via Benzinga
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
Medtronic Inc. Dividend Stock Analysis - Sunday, Sept. 29
Medtronic Inc. is a global medical device manufacturer with leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management, and other medical markets. Here are some highlights... 
Via Talk Markets
Top Analyst Reports For Nvidia, American Express & Wells Fargo
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., American Express Co., and Wells Fargo & Co., as well as two micro-cap stocks Elite Pharmaceuticals, Inc.... 
Via Talk Markets
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Explore the best dividend payouts from leading companies for sustainable, steady and growing income streams. 
Via InvestorPlace
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Key Takeaways From Becton Dickinson Analyst Ratings
Via Benzinga
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and... 
Via Benzinga
3 Healthcare Stocks to Buy Now to Profit From Aging Population Trends
With the baby boom turning into a retirement bonanza, investors should consider these senior-focused healthcare stocks. 
Via InvestorPlace
Topics Retirement
Exposures Pension
UnitedHealth, Edwards Lifesciences, First Citizens Bank And More: CNBC's 'Final Trades'
UnitedHealth Group was declared a "solid" healthcare company on CNBC. Cantor Fitzgerald analyst Sarah James maintains a price target of $591. 
Via Benzinga
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
The market previously supported a higher multiple for these undervalued stocks, making them attractive contrarian targets. 
Via InvestorPlace
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
The Nasdaq and S&P 500 hit record highs, but small caps retreated. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
BD Bolsters Portfolio With $4.2B Cash Deal For Edwards Lifesciences' Critical Care Group: Details
BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition enhances BD's portfolio with advanced AI-enabled monitoring... 
Via Benzinga
Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal
Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion. 
Via Investor's Business Daily
Trade Winds Turning: 3 Stocks Poised to Gain from Biden’s China Tariffs
Here are three potential stocks to buy that could benefit from China tariffs amidst the turning trade winds. 
Via InvestorPlace
Topics World Trade
Exposures Tariff
Biden's New Tariffs On Chinese Imports Are A 'Clear Giveaway' To These Two Tesla Rivals, Jim Cramer Says: 'I Like This Policy'
Jim Cramer has highlighted the potential benefits for U.S. automakers, particularly Ford and General Motors, following the Biden administration's decision to impose substantial tariffs on Chinese... 
Via Benzinga
Topics World Trade
Exposures Tariff
MarketBeat Week in Review – 4/29 - 5/3
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX... 
Via Benzinga
BDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024
BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
Curious to know how much these dividend aristocrats could grow in the next year? Here's the answer for several well-known shares. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.